|The impact of transcatheter atrial septal defect closure in the older population: a prospective study.|
|PMID: 20298984 Owner: NLM Status: MEDLINE|
|OBJECTIVES: We sought to prove that device closure of atrial septal defect (ASD) in older patients not only improves cardiac function but also results in symptomatic relief by improving functional class.
BACKGROUND: Atrial septal defect accounts for approximately 10% of all congenital cardiac defects. It is possible that ASD closure in older patients may derive benefits, though this is not well established. We therefore aim to prospectively assess the clinical status and functional class of older patients after transcatheter ASD closure.
METHODS: This was a prospective study of all patients age 40 years or more who underwent device closure of a secundum ASD between April 2004 and August 2006. Investigations including atrial and brain natriuretic peptide levels, electrocardiography, chest X-ray, transthoracic echocardiogram, 6-min walk test, and quality of life questionnaire were performed before and at 6 weeks and 1 year after the procedure.
RESULTS: Twenty-three patients (median age 70 years, 13 women) had transcatheter device closure of ASD. Median ASD size was 18 mm (range 9 to 30 mm). Median pulmonary artery pressure was 22 mm Hg (range 12 to 27 mm Hg). At 1 year, New York Heart Association functional class improved (p = 0.004) in 16 patients with significant improvement in 6-min walk-test distance (p = 0.004) and physical (p = 0.002) as well as mental health score (p = 0.03). There were no major complications. One year following closure there was a significant change in left ventricular end-diastolic (p = 0.001) and end-systolic dimensions (p = 0.001) and also significant reduction in right ventricular end-diastolic dimension (p < 0.001).
CONCLUSIONS: Our data demonstrated that ASD closure at advanced age results in favorable cardiac remodeling and improvement of functional class.
|Arif Anis Khan; Ju-Le Tan; W Li; Kostas Dimopoulos; Mark S Spence; Pak Chow; Michael J Mullen|
Related Documents :
|1156154 - Implantable pacemakers in children.
20561014 - Right ventricular apical contractility in acute pulmonary embolism: the mcconnell sign ...
19497444 - Incidence, risk factors, and outcome of traumatic tricuspid regurgitation after percuta...
4050554 - Aortic regurgitation associated with ventricular septal defects in adults. clinical cou...
10966034 - Postoperative suppressive therapy for thyroid adenomas.
16769504 - Orthodontic treatment planning software.
|Type: Journal Article|
|Title: JACC. Cardiovascular interventions Volume: 3 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2010 Mar|
|Created Date: 2010-03-19 Completed Date: 2010-06-17 Revised Date: 2014-09-05|
Medline Journal Info:
|Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States|
|Languages: eng Pagination: 276-81 Citation Subset: IM|
|Copyright (c) 2010 American College of Cardiology Foundation.. Published by Elsevier Inc. All rights reserved.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Atrial Natriuretic Factor / blood
Biological Markers / blood
Cardiac Catheterization* / adverse effects, instrumentation
Echocardiography, Doppler, Pulsed
Heart Septal Defects, Atrial / diagnosis, physiopathology, therapy*
Natriuretic Peptide, Brain / blood
Quality of Life
Recovery of Function
Septal Occluder Device
Ventricular Function, Left
Ventricular Function, Right
|0/Biological Markers; 114471-18-0/Natriuretic Peptide, Brain; 85637-73-6/Atrial Natriuretic Factor|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recommendations for successful training on methods of delivery of biologics for cardiac regeneration...
Next Document: Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients wi...